Journal of affective disorders · 2023
Down-regulated miR-16-2 in peripheral blood is positively correlated with decreased bilateral insula volume in patients with major depressive disorder.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yu, Yan Yushun, Wei Jinxue, Yang Xiao, Wang Min, Zhao Liansheng, Dou Yikai, Du Yue, Wang Qiang, Ma Xiaohong
Аннотация
BACKGROUND: The downregulated microRNA-16-2-3p (miR-16-2) had been believed to be associated with major depressive disorder (MDD). This study aimed to investigate the potential of miR-16-2 as a biomarker for MDD by analysing its expression levels, furthermore, to explore the relationship between miR-16-2, clinical symptoms and alterations in grey matter volume (GMV) in MDD patients.
METHODS: Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression level of miR-16-2 in 48 drug-naïve patients with MDD and 50 healthy controls (HCs). We conducted ROC curve analysis to assess the diagnostic value of miR-16-2 in MDD, and evaluated its ability to predict antidepressant response by reassessing depressive and anxiety symptoms after treatment. Voxel-based morphometry was carried out to explore alterations in regional GMV that may be associated with MDD. Pearson analysis was used to explore the relationship between miR-16-2 expression, clinical symptoms, and altered GMV in the brains of MDD patients.
RESULTS: We found that MDD patients had significantly downregulated miR-16-2 expression, which was negatively correlated with HAMD-17 and HAMA-14 scores, and had great diagnostic value for MDD (AUC = 0.806, 95 % CI: 0.721-0.891). In addition, MDD patients had significantly lower GMV in the bilateral insula and left superior temporal gyrus (STG_L) than HCs. GMV reduction in the bilateral insula was found to be correlated with miR-16-2 expression.
CONCLUSIONS: Our findings support the potential value of miRNA-16-2 as a biomarker for MDD. It also suggests that miRNA-16-2 may be associated with abnormal insula and involved in pathophysiological mechanisms of MDD.
METHODS: Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression level of miR-16-2 in 48 drug-naïve patients with MDD and 50 healthy controls (HCs). We conducted ROC curve analysis to assess the diagnostic value of miR-16-2 in MDD, and evaluated its ability to predict antidepressant response by reassessing depressive and anxiety symptoms after treatment. Voxel-based morphometry was carried out to explore alterations in regional GMV that may be associated with MDD. Pearson analysis was used to explore the relationship between miR-16-2 expression, clinical symptoms, and altered GMV in the brains of MDD patients.
RESULTS: We found that MDD patients had significantly downregulated miR-16-2 expression, which was negatively correlated with HAMD-17 and HAMA-14 scores, and had great diagnostic value for MDD (AUC = 0.806, 95 % CI: 0.721-0.891). In addition, MDD patients had significantly lower GMV in the bilateral insula and left superior temporal gyrus (STG_L) than HCs. GMV reduction in the bilateral insula was found to be correlated with miR-16-2 expression.
CONCLUSIONS: Our findings support the potential value of miRNA-16-2 as a biomarker for MDD. It also suggests that miRNA-16-2 may be associated with abnormal insula and involved in pathophysiological mechanisms of MDD.